Medicina
Departamento
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (122)
2024
-
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204
-
Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835
2023
-
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2
Human Mutation, Vol. 2023
-
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry
Genome Medicine, Vol. 15, Núm. 1
-
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Cancer Medicine, Vol. 12, Núm. 15, pp. 16142-16162
-
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197
-
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655
-
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
European Journal of Cancer, Vol. 190
-
Spatial predictors of immunotherapy response in triple-negative breast cancer
Nature, Vol. 621, Núm. 7980, pp. 868-876
-
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL
American Journal of Hematology, Vol. 98, Núm. 12, pp. 1856-1868
2022
-
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634
-
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Frontiers in Oncology, Vol. 12
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122
-
Common variants in breast cancer risk loci predispose to distinct tumor subtypes
Breast Cancer Research, Vol. 24, Núm. 1
-
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications biology, Vol. 5, Núm. 1, pp. 1061
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427
-
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
ESMO Open, Vol. 7, Núm. 2
-
Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))
European journal of human genetics : EJHG
-
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311